# Safety Study of Viaskin Peanut to Treat Peanut Allergy

> **NCT02916446** · PHASE3 · COMPLETED · sponsor: **DBV Technologies** · enrollment: 393 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **BIOLOGICAL:** Viaskin Peanut 250 mcg
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02916446
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-09-22
- **Final completion:** 2020-10-07
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2021-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02916446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02916446, "Safety Study of Viaskin Peanut to Treat Peanut Allergy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02916446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*